Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.

Drug metabolism and disposition: the biological fate of chemicals - 1 Jun 2010

Kearns Gregory L, Leeder J Steven, Gaedigk Andrea

Abstract excerpt

The impact of the CYP2C19*17 allele on the pharmacokinetics of pantoprazole and omeprazole in previously studied children (n = 40) was explored. When pantoprazole area under the plasma concentration versus time curve (AUC) was examined as a function of CYP2C19 genotype, a significantly lower AUC was observed for subjects identified as CYP2C19*1/*1 and *1/*17. For pantoprazole, a statistically significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Anti-Ulcer Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Aryl Hydrocarbon Hydroxylases

Share to Cytochrome P-450 CYP2C19

Share to Disulfides

Share to Metabolic Clearance Rate

Share to Omeprazole

Source

Open in PubMed Open full text

Identifiers

PMID: 20223877
DOI: 10.1124/dmd.109.030601
PMCID: PMC2879959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.PMID 20223877Read ↗

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.Semantic proximity Read ↗

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Semantic proximity Read ↗

Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.Semantic proximity Read ↗

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.Semantic proximity Read ↗

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.Semantic proximity Read ↗

Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study.Semantic proximity Read ↗

Omeprazole disposition in children following single-dose administration.Semantic proximity Read ↗

Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.Semantic proximity Read ↗

Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach.Semantic proximity Read ↗

Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.